Dr Kosiborod is an internationally recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, and quality care and outcomes.
Published: 01 July 2020
Prof Mark Petrie (University of Glasgow, Glasgow, UK) joins Dr Mikhail N Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US) to discuss heart failure in patients with diabetes with consideration to new data emerging from SGLT2 inhibitors and GLP-1 Receptor Agonists.
Diabetes and Heart Failure OutcomesWatch now
SGLT2 Inhibitors in Heart FailureWatch now
GLP-1 Receptor Agonists in Heart FailureWatch now